BEIJING - US pharmaceutical giant Pfizer's new research and development (R&D) center officially opened at BioPark in the ...

To advance fundamental scientific research in drug development, Bayer has fostered communication and collaboration with local academic institutions. In 2009 and 2014, the company established long ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

Bayer (BAYZF) stock in focus as the company inks a licensing deal with Puhe BioPharma to develop a cancer candidate targeting ...

Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged ...

A jury in Georgia has ordered Monsanto parent Bayer to pay nearly $2.1 billion in damages to a man who says the company’s ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...